Biotech · Private company · Pittsburgh, PA, US
CytoAgents, Inc.
Track this companyFree. Adds CytoAgents, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- CTO1681 10 µgPhase 2 · Cytokine Release SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CTO1681 10 µg Run-in / 20 µg TreatmentPhase 2 · Cytokine Release SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CTO1681 20 μgPhase 2 · Cytokine Release SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CTO1681 20 µg Run-in / 30 µg TreatmentPhase 2 · Cytokine Release SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CTO1681 30 μgPhase 2 · Cytokine Release SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell TherapyPHASE1_PHASE2 · RECRUITING · started Dec 28, 2023ClinicalTrials.gov NCT05905328 · fetched Nov 12, 2026
NIH awards4
- CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapyFiscal year 2026 · $936.4KNIH RePORTER 5R44CA295189-02 · fetched Nov 12, 2026
- CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapyFiscal year 2025 · $1.3MNIH RePORTER 1R44CA295189-01A1 · fetched Nov 12, 2026
- CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipientsFiscal year 2025 · $1MNIH RePORTER 5R44CA287634-02 · fetched Nov 12, 2026
- CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipientsFiscal year 2024 · $994.9KNIH RePORTER 1R44CA287634-01A1 · fetched Nov 12, 2026